Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ
Archives of ophthalmology (Chicago, Ill. : 1960) · 120 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Eye Institute
- Gobierno
- NEI NIH HHS
- Subvenciones
- National Eye Institute (U10 EY 11030)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2004-09-01 · Arch Ophthalmol · vol. 122 · número 9 · págs. 1306–14
- Editorial
- National Institutes of Health
- Citado
- 183 citas · más que el 91% de estudios similares · 2.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 15 trabajos
- Acceso
- De pago
- Áreas de investigación
- Retinal Development and Disorders · Retinal Diseases and Treatments · Fatty Acid Research and Health
- Palabras clave
- retinitis pigmentosa, docosahexaenoic acid, omega-3 fatty acids, vitamin A supplementation, retinyl palmitate, retinal degeneration, visual field sensitivity, subgroup analysis, visual acuity
- MeSH
- retina, erythrocyte membrane, humans, vision disorders, retinitis pigmentosa, vitamin e, docosahexaenoic acids, phosphatidylethanolamines, electroretinography, drug therapy, combination, administration, oral, double-blind method, visual fields, adolescent, adult, middle aged, female, male
12 autores
- Eliot L. Berson🇺🇸 · autor de correspondenciaHarvard University
- BERNARD A. ROSNER
- Michael A Sandberg
- Carol Weigel-DiFranco
- Ann Moser
- Robert J Brockhurst
- K C Hayes
- Chris A Johnson
- Ellen J Anderson
- Alexander R Gaudio
- Walter Churchill Willett
- Ernst J. Schaefer
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To determine whether docosahexaenoic acid will slow the course of retinal degeneration in subgroups of patients with retinitis pigmentosa who are receiving vitamin A.
Design
A cohort of 208 patients with retinitis pigmentosa, aged 18 to 55 years, were randomly assigned to 1200 mg of docosahexaenoic acid plus 15 000 IU/d of vitamin A given as retinyl palmitate (DHA + A group) or control fatty acid plus 15 000 IU/d of vitamin A (control + A group) and followed up over 4 years. Seventy percent of the patients in each group were taking vitamin A, 15 000 IU/d, prior to entry. We compared rates of decline in ocular function in the DHA + A vs control + A groups among the subgroups defined by use or nonuse of vitamin A prior to entry. We also determined whether decline in ocular function was related to red blood cell phosphatidylethanolamine docosahexaenoic acid level, dietary omega-3 fatty acid intake, or duration of vitamin A use. Main outcome measures were Humphrey Field Analyzer visual field sensitivity, 30-Hz electroretinogram amplitude, and visual acuity.
Results
Among patients not taking vitamin A prior to entry, those in the DHA + A group had a slower decline in field sensitivity and electroretinogram amplitude than those in the control + A group over the first 2 years (P =.01 and P =.03, respectively); these differences were not observed in years 3 and 4 of follow-up or among patients taking vitamin A prior to entry. In the entire cohort, red blood cell phosphatidylethanolamine docosahexaenoic acid level was inversely related to rate of decline in total field sensitivity over 4 years (test for trend, P =.05). This was particularly evident over the first 2 years among those not on vitamin A prior to entry (test for trend, P =.003). In the entire control + A group, dietary omega-3 fatty acid intake was inversely related to loss of total field sensitivity over 4 years (intake, or =0.20 g/d; P =.02). The duration of vitamin A supplementation prior to entry was inversely related to rate of decline in electroretinogram amplitude (P =.008).
Conclusions
For patients with retinitis pigmentosa beginning vitamin A therapy, addition of docosahexaenoic acid, 1200 mg/d, slowed the course of disease for 2 years. Among patients on vitamin A for at least 2 years, a diet rich in omega-3 fatty acids (> or =0.20 g/d) slowed the decline in visual field sensitivity.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.